Increasing radiation dose improves immunotherapy outcome and prolongation of tumor dormancy in a subgroup of mice treated for advanced intracerebral melanoma

Cancer Immunology, Immunotherapy

Volumn 65, Issue 2, 2016, Pages 127-139

  Smilowitz, Henry M ^a   Micca, Peggy L ^b   Sasso, Daniel ^a   Wu, Qian ^a   Dyment, Nathanial ^a   Xue, Crystal ^a   Kuo, Lynn ^c  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Immunotherapy; Intracerebral melanoma; Radiation dose; Radiation therapy; Tumor dormancy

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADVANCED INTRACEREBRAL MELANOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; GENETIC TRANSFECTION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BRAIN NEOPLASMS; CANCER STAGING; DISEASE COURSE; DISEASE MODEL; EXPERIMENTAL MELANOMA; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIATION RESPONSE; RADIOTHERAPY; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASM STAGING; RADIATION DOSAGE; TUMOR BURDEN; X-RAY THERAPY;

EID: 84955675674     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1772-7     Document Type: Article

References (36)

1. Walbert T, Gilbert MR (2009) The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol 14:299–306. doi:10.1007/s10147-009-0916-1
2. Langley RR, Fidler IJ (2013) The biology of brain metastasis. Clin Chem 59:180–189. doi:10.1373/clinchem.2012.193342
3. Smilowitz HM, Sasso D, Lee E, Goh G, Micca PL, Dilmanian FA (2013) Therapy model for advanced intracerebral B16 mouse melanoma using radiation therapy combined with immunotherapy. Cancer Immunol Immunother 62:1187–1197. doi:10.1007/s00262-013-1423-9
4. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM (2011) Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17:1603–1615. doi:10.1158/1078-0432.CCR-10-2563
5. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang HQ, Nuno MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JG, Hawkins ES, Patil CG, Black KL, Yu JS (2013) Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 62:125–135. doi:10.1007/s00262-012-1319-0
6. Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834–846. doi:10.1038/nrc2256
7. Ossowski L, Aguirre-Ghiso JA (2009) Dormancy of metastatic melanoma. Pigment Cell Melanoma Res 23:41–56. doi:10.1111/j.1755-148X.2009.00647.x
8. Almog N (2010) Molecular mechanisms underlying tumor dormancy. Cancer Lett 294:139–146. doi:10.1016/j.canlet.2010.03.004
9. Barkan D, Green JE, Chambers AF (2010) Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 46:1181–1188. doi:10.1016/j.ejca.2010.02.027
10. Bragado P, Sosa MS, Keely P, Condeelis J, Aguirre-Ghiso JA (2012) Microenvironments dictating tumor dormancy. Recent Results Cancer Res 195:25–39. doi:10.1007/978-3-642-28160-0_3
11. Rocken M (2010) Early tumor dissemination, but late metastasis: insights into tumor dormancy. J Clin Invest 120:1800–1803. doi:10.1172/JCI43424
12. Wells A, Griffith L, Wells JZ, Taylor DP (2013) The dormancy dilemma: quiescence versus balanced proliferation. Cancer Res 73:3811–3816. doi:10.1158/0008-5472.CAN-13-0356
13. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R (2011) Effect of radiotherapy after breast conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707–1716. doi:10.1016/S0140-6736(11)61629-2
14. Hensel JA, Flaig TW, Theodorescu D (2013) Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol 10:41–51. doi:10.1038/nrclinonc.2012.207
15. Mladenov E, Magin S, Soni A, Lliakis G (2013) DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol 3:113. doi:10.3389/fonc.2013.00113
16. Burnette B, Weichselbaum RR (2013) Radiation as an immune modulator. Semin Radiat Oncol 23:273–280. doi:10.1016/j.semradonc.2013.05.009
17. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903–907. doi:10.1038/nature06309
18. Liang H, Deng L, Chmura S, Burnette B, Liadis N, Darga T, Beckett MA, Lingen MW, Witt ME, Weichselbaum RR, Fu Y-X (2013) Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol 190:5874–5881. doi:10.4049/jimmunol.1202612
19. Smilowitz HM, Slatkin DN, Lubimova N, Blattman H, Brauer-Krisch E, Bravin A, Di Michiel M, Stepanek J, Le Duc G, Gebbers J-O, Laissue JA (2006) Synergy of gene-mediated immunoprophylaxis and microbeam radiation therapy for advanced intracerebral rat 9L gliosarcomas. J Neurooncol 78:135–143. doi:10.1007/s11060-005-9094-9
20. Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Fomenti SC (2014) Combinations of immunotherapy and radiation in cancer therapy. Front Oncol 4:325. doi:10.3389/fonc.2014.00325
21. Finkelstein SE, Timmerman R, McBride WH, Schaue D, Hoffe SE, Mantz CA, Wilson GD (2011) The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol 2011:439752. doi:10.1155/2011/439752
22. Chow KKH, Hara W, Lim M, Li G (2015) Combining immunotherapy with radiation for the treatment of glioblastoma. J Neurooncol 123:459–464. doi:10.1007/s11060-015-1762-9
23. Soukup K, Wang X (2015) Radiation meets immunotherapy—a perfect match in the era of combination therapy? Int J Rad Biol 91:299–305. doi:10.3109/09553002.2014.995383
24. Shahabi V, Postow MA, Tuck D, Wolchok JD (2015) Immune-priming of the tumor microenvironment by radiotherapy. Am J Clin Oncol 38:90–97. doi:10.1097/COC.0b013e3182868ec8
25. Wattenberg MM, Fahim A, Ahmed MM, Hodge JW (2014) Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy. Radiat Res 182:126–138. doi:10.1667/RR13374.1
26. Kershaw MH, Devaud C, John LB, Westwood JA, Darcy PK (2013) Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology 2:e25962. doi:10.4161/onci.25962
27. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373–377. doi:10.1038/nature14292
28. Filatenkov A, Baker J, Mueller AMS, Kenkel J, Ahn G-O, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, Shizuru JA, Negrin RN, Engelman EG, Strober S (2015) Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res 21:3727–3739. doi:10.1158/1078-0432.CCR-14-2824
29. Persa E, Balogh A, Sáfrány G, Lumniczky K (2015) The effect of ionizing radiation on regulatory T cells in health and disease. Cancer Lett 368:252–261. doi:10.1016/j.canlet.2015.03.003
30. Sridharan V, Schoenfeld JD (2015) Immune effects of targeted radiation therapy for cancer. Discov Med 19:219–228
31. Gandhi SJ, Minn AJ, Vonderheide RH, Wherry EJ, Hahn SM, Maity A (2015) Awakening the immune system with radiation: optimal dose and fractionation. Cancer Lett 368:185–190. doi:10.1016/j.canlet.2015.03.024
32. Zeng J, Harris TJ, Lim M, Drake CG, Tran PT (2013) Immune modulation and stereotactic radiation: improving local and abscopal responses. Biomed Res Int 2013:658126. doi:10.1155/2013/658126
33. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S (2009) Fractionated but not single dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15:5379–5388. doi:10.1158/1078-0432.CCR-09-0265
34. Burnette B, Weichselbaum RR (2015) The immunobiology of ablative radiation. Semin Radiat Oncol 25:40–45. doi:10.1016/j.semradonc.2014.07.009
35. Mondini M, Nizard M, Tran T, Mauge L, Loi M, Clemenson C, Duque D, Maroun P, Louvet E, Adam J, Badoual C, Helley D, Dransart E, Johannes L, Vozenin MC, Perfettiini JL, Tartour E, Deutsch E (2015) Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer. Mol Cancer Ther 14:1336–1345. doi:10.1158/1535-7163.MCT-14-1015
36. Hainfeld JF, Slatkin DN, Smilowitz HM (2004) The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 49:N309–N315. doi:10.1088/0031-9155/49/18/N03